<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1480">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141890</url>
  </required_header>
  <id_info>
    <org_study_id>1679041</org_study_id>
    <nct_id>NCT05141890</nct_id>
  </id_info>
  <brief_title>Probiotics for Inflammation in Pediatric Chronic Pain</brief_title>
  <official_title>Probiotics for Inflammation in Pediatric Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine benefits of a probiotic for youth with chronic pain and obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the current study: (1) examine whether an 8-week supplement of a single-strain&#xD;
      probiotic (Lactobascillus Plantarum, Lp299v) reduces systemic inflammation; (2) determine&#xD;
      whether reductions in systemic inflammation will correlate with reductions in pain,&#xD;
      disability, mood impairment and changes in mechanical pain threshold and mechanical pain&#xD;
      sensitization; (3) Explore whether reductions in systemic inflammation will correlate with&#xD;
      reductions in other outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in systemic inflammation - CRP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in circulating C-Reactive Protein after 8 weeks of probiotic supplement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Worst Pain intensity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in worst pain intensity (based on a 0-10 numeric rating scale) over the past 2 weeks after 8 weeks of probiotic supplement.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given the probiotic supplement Lp299v. The supplement is taken by mouth in the form of capsules. Participants will undergo a screening visit. After 8 weeks of taking Lp299v, they will return for their final visit. Blood will be drawn before and after the 8-week intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus Plantarum</intervention_name>
    <description>Dietary Supplement: Lp299v. Lp299v is a commercially available probiotic supplement manufactured and distributed by Next Foods.</description>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>Lp299v</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female biological sex&#xD;
&#xD;
          2. 13-17 years of age&#xD;
&#xD;
          3. Body Mass Index â‰¥95th percentile for sex and age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Probiotic (or prebiotic) supplement use or antibiotic use within the past month&#xD;
&#xD;
          2. Chronic inflammatory or autoimmune disease with the exception of well-controlled&#xD;
             hypothyroidism or intermittent or mild persistent asthma not requiring the use of&#xD;
             daily inhaled steroids&#xD;
&#xD;
          3. Chronic pain conditions other than headache or migraine&#xD;
&#xD;
          4. Patients who have had a poor response to blood draw or immunizations in the past&#xD;
&#xD;
          5. Chronic use of medications known to alter gastrointestinal function or inflammation&#xD;
             (e.g. metformin, non-steroidal anti-inflammatory medications)&#xD;
&#xD;
          6. Any condition that, in the investigator's opinion, may compromise study participation&#xD;
             or may confound the interpretation of the study results&#xD;
&#xD;
          7. Use of illicit drugs&#xD;
&#xD;
          8. Females who are pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Keri Hainsworth, PhD</last_name>
    <phone>4142666306</phone>
    <email>khainswo@mcw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brynn LiaBraaten, BA</last_name>
    <phone>4142667264</phone>
    <email>bliabraaten@chw.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53185</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Keri Hainsworth, PhD</last_name>
      <phone>414-266-6306</phone>
      <email>khainswo@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Keri Hainsworth</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

